**CASE REPORT**

A Caucasian 79-year-old female was referred to the Internal Medicine Consultation for etiologic investigation of erythrocytosis (haemoglobin 20.5 g/dL, hematocrit 62%) and segmental pulmonary thromboembolism. Her past medical history included arterial hypertension, dyslipidemia and obesity. After the complementary study carried out, the diagnosis of polycythemia vera was made (heterozygous V617F mutation in the JAK2 gene). The patient was then referred to the Hematology Consultation and started hydroxyurea (initially 500mg twice daily), along with phlebotomies. She was already under systemic anticoagulation. The patient had a good response, with hematocrit control.

After 5 months of beginning with hydroxyurea, she developed asymptomatic and progressive longitudinal dark brown bands involving all her fingernails (Figure 1) and toenails (Figure 2). The bands were well-defined and with different widths. In some fingernails, the pigmentation bands spread proximally underneath the translucent cuticles, but the nail folds were not affected (Pseudo-Hutchinson’s sign). There was no nail thickening or atrophy. No history of trauma and there was no history of melanoma in her family. It was assumed drug-induced longitudinal melanonychia due to hydroxyurea. No other side effects of the drug were seen, so it was decided to maintain the drug due to the risk of another thrombotic event with the suspension.

Hydroxyurea is a cytostatic drug typically used for the treatment of myeloproliferative disorders and is generally a well-tolerated drug. Melanonychia is a rare side effect of this drug that occurs only in 4.3% of the patients. Besides, the involvement of all 20 nails is even rarer and only five cases were reported. The time between the initiation of hydroxyurea and the onset of the melanonychia varies from 4 weeks to 5 years. Other differential diagnoses should be considered such as physiological causes, repetitive trauma, onychomycosis or underlying systemic disease. In the case of a single affected nail, subungual melanoma should be ruled out, especially in the presence of the Hutchinson’s sign (nail pigmentation affecting also the cuticle and nail fold). So, this drug side effect should be known to avoid misdiagnosis. After discontinuation of hydroxyurea, melanonychia generally disappears as the nail grows. However, the decision to stop therapy needs to be pondered because of the risk of thrombotic events. If no more serious cutaneous effects occur, we think the drug should not be discontinuing.

**REFERENCES**


**Palabras clave:** enfermedades de las uñas, hidroxiurea, policitemia vera.

**Keywords:** nail diseases, hydroxyurea, polycythemia vera.